Samsung Biologics expands collaboration with LigaChem Biosciences for ADC development By Investing.com



  • Samsung (KS:) Biologicals on offer ADC service in a new dedicated facility
  • Extended collaboration reflects successful partnerships and expertise

INCHEON, South Korea, Jan. 8, 2025 /PRNewswire/ — Samsung Biology (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced to increase collaboration with LigaChem Biosciences (: 141080) in provide antibody– drug conjugate (ADC) services.

Samsung Biology will support a series of LigaChem Biosciences’ ADCs programs of Samsung Biologics’ new dedicated ADC facility. The two companies are already collaborating on ADC programs for the treatment of solid tumors. LigaChem Biosciences is a biotech pioneering research and development of ADC candidates.

“The latest collaboration will be even stronger Samsung Biologics’ capabilities at all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapeutics to patients,” said John RimCEO and President of Samsung Biology. “We look forward to supporting our clients’ new ADC pipelines, ensuring the highest quality and timelines are met.

“This collaboration with Samsung Biology will be an important step towards strengthening the supply chain of high-quality ADC drugs and improving the competitiveness of both companies in the global ADC market,” said Yong-Zu KimPresident and CEO of LCB. “By exploitation Samsung Biologics’ extensive experience as a CDMO, we can accelerate the development of our pipeline and quickly bring new ADC treatments to patients”.

Samsung Biologics’ The ADC facility is a segregated suite, with a 500-liter reactor, that supports the development and manufacture of ADC therapies. Building on the company’s track record of expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics’ ADC’s service coverage includes late-stage discovery and conjugatiin.

Samsung Biology also makes active investments through Samsung Life (KS:) Science Fund of biotech companies pioneering ADC linker technologies, toolbox, and protein engineering.

For more information, visit: https://samsungbiologics.com/services/adc

About Samsung Biologics Co., Ltd.

Samsung Biology (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors from small to large scales to serve a variety of client needs. Maximizing operational efficiency and expanding our capabilities in response to the growing needs of biomanufacturing, Samsung Biology offers a combined 604 kL total capacity in Bio Campus I. The company is launching Bio Campus II with the construction of Plant 5, which will be operational in April 2025, which will add 180 kL biomanufacturing capacity. In addition, Samsung Biologics America allows the company to work closer to clients based in US and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in a dedicated ADC facility, mRNA technologies, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.

About LigaChem Biosciences

LigaChem Biosciences, Inc. (LCB) is a clinical stage biopharmaceutical company dedicated to discovering and developing new medicines by using medicinal chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with chronic diseases. unmet medical needs. LCB develops sustainable pipelines in therapeutic areas within antibiotics, anti-fibrotics, oncology, and ADC platform technology. For more information, visit https://ligachembio.com/

Contact Samsung Biologics
Claire KimHead of Global Marketing Communications
[email protected]

LigaChem Biosciences Contact
Daeyoung JeongHead of Investor Relations/ Business Development
[email protected]





Source link

  • Related Posts

    Italy’s Meloni sees Trump defend Western interests, joins Ukraine By Reuters

    By Angelo Amante and Crispian Balmer ROME (Reuters) – Italian Prime Minister Giorgia Meloni, one of the European leaders closest to Donald Trump, said on Thursday she believed the U.S.…

    Arrow EC Income Advantage Alternative Fund Series ETF declares a dividend of CAD 0.081

    Arrow EC Income Advantage Alternative Fund Series ETF declares a dividend of CAD 0.081 Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *